Martin Wermke MD; ESMO 2025: Initial Therapy with Bi-Specific T-cell Engager Tarlatamab Promises Better Outcomes in Patients with Small Cell Lung Cancer

episode
Audio Journal of Oncology Podcast not yet transcribed
0